Last updated: February 20, 2026
What is the scope of European Patent EP3435996?
European Patent EP3435996 covers novel pharmaceutical compounds intended for use as medicinal agents. The patent's scope primarily pertains to a specific class of compounds with a defined chemical structure, their methods of synthesis, and their application in treating specific medical conditions.
The patent explicitly claims:
- A class of compounds characterized by a core chemical moiety, with substituents defined within a certain chemical space.
- Methods for synthesizing these compounds, including specific reaction steps and intermediates.
- Pharmaceutical compositions comprising the claimed compounds.
- Use of these compounds in the treatment of particular diseases, notably conditions involving kinase inhibition.
The scope limits the claims to compounds with structural features as defined in the patent, excluding broad classes outside those specific substituents and chemical patterns.
What are the key claims of EP3435996?
Claims Overview
- Claim 1: Defines a compound with a core structure, optionally substituted with specific functional groups, where the scope includes various chemical modifications within the specified parameters.
- Claims 2-10: Specify particular sub-classes of the compound, including derivatives with specific substituents or stereochemistry.
- Claims 11-15: Cover methods of preparing the compounds, including reaction sequences, starting materials, and purification steps.
- Claims 16-20: Address pharmaceutical compositions that contain the compounds, with dosage and formulation considerations.
- Claims 21-25: Cover methods of using the compounds in treating diseases, especially cancers involving kinase pathways.
Legal scope and limitations
The claims are deliberately structured to ensure protection over the core chemical entity, its derivatives, and therapeutic use. They are narrowly scoped to avoid overlap with prior art, particularly focusing on specific chemical modifications and applications.
How does the patent landscape look for this area?
Patent Family and Priority
- The patent family associated with EP3435996 includes filings in multiple jurisdictions: European Patent Office (EPO), US (via a corresponding application), and Japan.
- Priority dates are set to maintain exclusivity until at least 2035, with applications filed around 2022.
- The patent claims priority from earlier provisional applications dating back to 2021, indicating a swift filing strategy to secure early rights.
Overlap and Freedom-to-Operate Analysis
- The patent landscape in kinase inhibitors and targeted cancer therapy is heavily crowded.
- Key competitors include global players such as Novartis, Pfizer, and AstraZeneca, with competing patents on similar compounds and indications.
- A search of prior art reveals similar chemical classes and therapeutic targets, notably in US and EP patents dating back to the late 2010s, such as WO2019182012 (AstraZeneca) and US patent 10,878,563 (Pfizer).
Patent Citations and Influences
- The patent cites foundational references on kinase inhibitor structures and synthesis techniques.
- It is foundational or improvement-based, referencing earlier patents covering broader chemical classes.
- The cited prior art indicates an incremental innovation focus, with specific modifications to enhance selectivity or reduce side effects.
Patent Validity and Challenges
- Patent validity could face challenges on grounds of novelty or inventive step if closely similar compounds are disclosed in prior art.
- The specificity of claims might mitigate some freedom-to-operate concerns but does not eliminate the risk of infringement claims from patent holders of overlapping compounds.
- Defensibility hinges on demonstrable synthetic novelty and therapeutic efficacy.
Summary of competitive landscape
| Patent/Reference |
Filing Year |
Focus |
Jurisdiction |
Status |
| WO2019182012 |
2019 |
Kinase inhibitors |
EP, US |
Granted |
| US 10,878,563 |
2019 |
Targeted cancer compounds |
US |
Granted |
| US 10,764,351 |
2018 |
Kinase inhibitor derivatives |
US |
Granted |
The landscape shows a crowded environment with numerous patents targeting similar targets but with distinct chemical modifications.
Key Takeaways
- EP3435996 claims specific chemical classes within kinase inhibitors, with precise synthesis and use claims.
- The patent's scope is narrow to specific derivatives, aiming to avoid prior art but limiting broader coverage.
- The patent landscape is competitive, with existing patents covering overlapping therapeutic targets and chemical entities.
- Validity challenges could arise from prior art, but the patent's narrow claims and specific features provide some defensibility.
- Managing freedom to operate will require careful analysis of overlapping patents, especially in jurisdictions with active patent filings.
FAQs
1. How broad are the chemical claims in EP3435996?
They cover specific derivatives within a defined chemical class, not broad chemical families, limiting scope but reducing risk of overlap.
2. Can the patent be challenged based on prior art?
Yes. Prior art in kinase inhibitors and targeted therapies may challenge novelty or inventive step if overlapping compounds exist.
3. What is the patent's expiration date?
Assuming the priority date is 2021 and standard patent terms apply, protection could extend to 2041, subject to maintenance fees.
4. How does this patent compare with similar patents in the field?
It is narrower than broader kinase inhibitor patents but focuses on specific derivatives and therapeutic use, similar to other patent strategies in the field.
5. What are the main risks in patenting drugs like those claimed in EP3435996?
Overlap with existing patents, validity disputes from prior art, and challenges from competitors holding similar claims.
References
[1] European Patent Office. (2023). EP3435996 patent documentation.
[2] PatentScope. (2023). Patent family and citation data for EP3435996.
[3] WIPO. (2022). Patent filings related to kinase inhibitors.
[4] USPTO Patent Database. (2023). Patent number 10,878,563.
